Login
Intellia Therapeutics NASDAQ: NTLA
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
| Name | Intellia Therapeutics |
| Ticker | NTLA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 23.49 |
| 52W Low/High | 9.44 / 26.31 |
| Market cap | 1.2 B |
| 1Y Total Return |
109.73%
Strong |
| 1Y Volatility |
85.01%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
Details
| Ticker | NTLA |
| Name | Intellia Therapeutics |
| ISIN | US45826J1051 |
| CUSIP | 45826J105 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 10/21/20
| Close Price | 23.49 |
| 52W Low/High | 9.44 / 26.31 |
| Market cap | 1.2 B |
| 1Y Total Return |
109.73%
Strong |
| 1Y Volatility |
85.01%
High Risk |
| Beta | 2.17 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -228.9% |
| Cash from Op. / Cur. Liabilities | -0.60 |
| Diluted Earnings / Share | -2.31 |
| ROE | - |
| ROIC | -69.4% |
| Price / Revenue | 24.7 |
| Price / Book | 3.6 |
| Price / CF | -35.6 |
| Current Ratio | 7.5 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.07 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
51
|
37
|
29
|
23
|
9
|
-
|
|
| Gross Profit |
51
|
37
|
29
|
23
|
9
|
-
|
|
| R&D |
132
|
92
|
85
|
48
|
20
|
-
|
|
| EBITDA |
-110
|
-84
|
-79
|
-44
|
-22
|
-
|
|
| Operating Income |
-121
|
-96
|
-87
|
-47
|
-22
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
53
|
46
|
43
|
35
|
19
|
-
|
|
| EPS exc. Extra |
-2.31
|
-2.01
|
-2.10
|
-1.29
|
-22.89
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
491
|
352
|
340
|
265
|
311
|
-
|
|
| Cash, Eq & Invt ShortTerm |
437
|
271
|
306
|
241
|
301
|
-
|
|
| Total Current Assets |
446
|
307
|
318
|
246
|
303
|
-
|
|
| Total Non-Current Assets |
44
|
45
|
22
|
19
|
8
|
-
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Total Liabilities |
139
|
76
|
60
|
77
|
87
|
-
|
|
| Total Current Liabilities |
59
|
38
|
25
|
26
|
22
|
-
|
|
| Long Term Debt |
80
|
37
|
35
|
51
|
65
|
-
|
|
| Shareholder equity |
352
|
277
|
279
|
188
|
224
|
-
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-35
|
-70
|
-78
|
-49
|
49
|
-
|
|
| Depreciation |
6
|
5
|
4
|
2
|
1
|
-
|
|
| Cash from Investing |
147
|
-229
|
-7
|
-9
|
-4
|
-
|
|
| Capex |
6
|
6
|
7
|
9
|
4
|
-
|
|
| Cash from Financing |
203
|
43
|
150
|
-1
|
235
|
-
|
|
| Stock Issued |
202
|
42
|
149
|
-2
|
169
|
-
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
48
|
-296
|
-95
|
-53
|
-
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
7.5
|
8.0
|
12.6
|
9.3
|
14.0
|
-
|
|
| Financial Leverage D/E |
0.07
|
0.07
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-69.4%
|
-65.3%
|
-2,501.3%
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available